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Abstract— Sensor Technology and Devices Ltd, a sensor-based 
business spun out from the University of Ulster in Belfast 7 years 
ago, has found that a specific set of technologies it has developed 
during that period now sits at the epicentre of a well defined 
clinical/technological watershed. Wireless vital signs monitoring 
solutions have moved from development to clinical trial to the 
excitement of both the healthcare and technology communities. 
I. INTRODUCTION 
The percentage of the population classified as being elderly 
has been predicted to increase dramatically in size over the 
next 30-40 years. Figures produced by the World Health 
Organisation (WHO) anticipate an increase from around 600 
million in the year 2000 to close to 2 billion by the year 2050 
[1]. By 2050, 22 percent of the world’s population will be 
over 60 [2] – in Europe it will be over 30 % [3]. In addition, 
according to the WHO, approximately 10% of the population 
experience some form of disability.  Already 21% of people 
above the age of 50 have severe vision, hearing and/or 
mobility problems.   
The prevalence of diabetes and cardiovascular disease 
increases with advancing age. Additionally, the age-related 
demographics of these diseases are changing and they are 
affecting people at progressively younger ages.  As a result we 
are now witnessing a shift in the burden of illness from acute 
to chronic conditions which has given rise to a generation of 
people living with long-term illness and disability. 
The combination of an ageing population and the increased 
need for chronic disease management is driving up health 
costs and making significant demands on an already stretched 
health and social care provision. According to the Continua 
Health Alliance, in developed countries, between 40 to 70% 
of healthcare spending is related to the care of chronic 
conditions, especially those affecting the elderly.  
According to the WHO, chronic diseases and their risk 
factors now pose a serious threat to global health. “Health 
care is heading toward one of the biggest societal crises that 
we (the US) can imagine, both here and abroad. Because 
health care already accounts for 15% of the GDP in the U.S., 
we can't, as a society, afford to devote any more of our 
economy to it.” [4] 
There is a widely recognised need to radically change 
Healthcare provision, presently based on an acute care model, 
to make it more suited to the ongoing management of chronic 
disease and hence move towards a preventative care model. 
This has to involve changing the existing Health Care systems 
and their associated technologies.  
Modern healthcare systems have generally evolved around 
the treatment of acute disease and are therefore largely 
organised to cope with patients’ episodic and acute needs. 
Chronic conditions have now overtaken acute problems, 
constituting the major, and growing, healthcare burden. 
Unfortunately, using a reactive acute care model to address 
the needs of a population that now suffers primarily from 
chronic conditions, i.e. waiting until something goes seriously 
wrong rather than optimally managing the chronic condition 
on an ongoing basis, leads to excessive, inefficient and 
ineffective use of secondary care services. As a consequence, 
chronic conditions now consume up to 75-85% of  health and 
social care spend in developed countries, causing a growing 
economic strain on the world’s healthcare systems [3].  
It is widely agreed (e.g. by the WHO and the EC) that it is 
imperative that healthcare leadership implement a more 
sustainable form of care, improving healthcare quality while 
reducing unnecessary costs. This is to be achieved by shifting 
away from today’s reactive model of care to an integrated 
approach which enables, encourages and supports individuals 
and their families to continuously monitor and manage their 
health from the comfort of their homes, cars, work place, etc., 
avoiding, to a great extent, costly acute intervention. The 
emphasis now is therefore on “self-management”, 
“personalised health”, “pervasive healthcare” and 
“preventative healthcare”; terms reflecting key aspects of the 
new approach. 
It has been shown that home-based or Ambient healthcare 
delivery, where appropriate, is much less costly coupled and 
the patient’s perceived quality of life is generally much higher. 
Home-based care is less expensive on a ‘per day’ basis and 
more appreciated by the patient. More importantly, it is 
generally more effective, therapeutically and financially, to 
encourage and support the patient to manage their chronic 
condition at home; to detect and act on symptoms as early as 
possible.  
A. Potential Solutions 
The development of sensor and related technologies that 
enable the monitoring of a patient’s health and lifestyle at 
home and ‘while on the move’ promise major improvements 
to the quality of healthcare while driving down costs. There is 
therefore a need of revolutionary ‘Ambient Assisted Living’ 
(AAL) systems which involve novel sensor technologies, 
mobile technology, home-based medical equipment, 
embedded systems, wearable systems, ambient intelligence, 
etc. which are capable of conveniently, discreetly and robustly 
monitoring patients in their homes and while performing their 
daily activities without interfering significantly with their 
comfort or lifestyle. Early studies indicate that these 
technology-enabled, personalised programs can, with further 
developments, form a complete solution for sustained, 
efficient, quality health care.  
It has been estimated that the prevention and effective 
management of chronic conditions is 20% medicine – 80% 
‘other’ [5]. By concentrating on the 80% non-medicinal 
aspects, better healthcare can be provided without the 
escalating cost. Solutions to the monitoring and treatment of 
many chronic diseases can therefore be offered from a number 
of technological perspectives, all of which aim to provide a 
level of independence within the home environment (and 
beyond) and the effective early detection and treatment of 
conditions before they necessitate costly emergency 
intervention. According to the EC definition, AAL is the 
consolidation of the necessary technologies, systems and 
services required to delivery this new healthcare provision. 
One of the key goals of AAL is the delivery of preventative 
support rather than (simply) reactive intervention. This 
involves the intelligent processing of information gathered 
concerning the patient’s environment, lifestyle and vital signs. 
The patient (and/or family) is/are effectively encouraged to 
take some responsibility for their healthcare, and medical 
conditions can be more effectively managed to the benefit of 
all concerned. The services which AAL can offer within the 
home environment should also be available once the person 
leaves their home, goes for a walk, gets into their car, goes to 
their GP, etc. Future health care must be ‘Personalised’ and 
‘Connected’. It is important to stress the ‘at work’ and ‘in 
community’ parts of AAL – this is one of the main ways that 
it delineates itself from its ‘Tele’ predecessors. 
B. Barriers to the success of Ambient Assisted Living 
Although early trials, pilot studies and a few major 
programs have had promising results, the widespread adoption 
of such ‘telemonitoring’ and AAL has to date been very slow 
– much too slow to radically improve health and quality of life 
and dramatically reduce healthcare costs. Several key barriers 
exist to the more widespread use of such exciting technology.  
These include  
1. Suitable Sensor & Associated Technologies 
2. Device Interoperability      
3. Connected HealthCare Systems 
4. Routes to Market   
 
II. ST+D’S EXPERIENCES 
A. Suitable Sensor & Associated Technologies 
A major remaining stumbling block to the successful design 
and development of monitoring systems capable of being 
applied to and functioning reliably on real patients, under real 
conditions for an extended period of time with sufficient 
robustness is the design of the sensors [6], [7]. 
This rather surprising observation is a consequence of the 
standard approach taken by engineers while designing 
wearable/portable monitoring devices. Invariably the 
engineers involved, who are generally specialists in IT, 
Electronics etc., start with the monitoring device, hardware, 
software, telemetry, etc and leave the ‘simple’ sensors to be 
added on at the end. Unfortunately, electrodes are not just 
‘pieces of conductive metal’ as is often evidently assumed (for 
example, silver chloride, the best electrode material for most 
non-invasive biosignal monitoring applications, is in fact very 
resistive), nor are all sensing problems miraculously solved by 
making sensors smaller. Key problems to be overcome 
include the convenient attachment of sensors in their correct 
locations, the comfortable and discrete wearing of the sensors 
for prolonged periods and the avoidance of motion-induced 
artefacts. 
 
Fig. 1  ST+D’s Wireless Vital Signs Monitor  
ST+D is a technical innovator in the AAL field. One of 
ST+D’s key product ranges is the body-worn sensor patch and 
telemetry system. The associated technology has been 
developed for personalised healthcare and provides : 
• Miniaturised wireless telemetry 
• Reduced motion artefact  
• Multiple combinations of vital signs integrated into a 
single, disposable, low-cost sensor patch. 
• On-body processing and recognition algorithms allowing 
a huge reduction in the data sent, thus improving battery 
life and ease of data assimilation by clinicians 
• Unique patient identification ‘biometric’ derived from the 
vital signs for security and privacy 
 
Some of specific technologies developed include: 
• Motion tolerant ECG, up to 3 leads  
• Low-power processing of ECG arrhythmia recognition 
algorithms – 10 arrhythmia types recognised 
• Motion tolerant respiration from chest patch (no band 
round the chest) 
• SP02 measurement from the same chest patch, presently 
through proof-of-concept development. 
• 3-axis motion and temperature measurement.   
• Patented user identification from ECG 
• Range of wireless protocols/combinations for use in 
various monitoring applications – hospital, at home,.. 
B. Device Interoperability 
If sophisticated monitoring devices and associated systems 
are to be successfully introduced into the general Healthcare, 
the devices must be fully interoperable with each other and 
with other information sources. ‘Interoperability’ is the ability 
of a system or a product to work with other systems or 
products without special effort on the part of the 
patient/customer. For medical devices to be able to function 
efficiently with other products they all have to adhere to some 
form of widely accepted standards. No standards presently 
exist that fully define interoperability among medical devices 
and systems, thus the market is unable to fully exploit the 
technical solutions presently available. International 
interoperability standards will require the collaboration of all 
the key participants involved in the Healthcare provision and 
will involve the development of public policy, regulations, re-
imbursement, etc. without which such standards will not gain 
widespread acceptance. Policy makers, regulators and industry 
leaders must collaborate to remove policy barriers to standards 
development worldwide and create new policies and 
incentives to advance harmonisation  
The Continua Health Alliance was formed in 2006 by 
technology, medical device and health and fitness industry 
leaders with the aim of “establishing an ecosystem/market of 
connected personal health and fitness products and services 
making it possible for patients, caregivers and healthcare 
providers to more proactively address ongoing health care 
needs”[3] and to thus accelerate the healthcare technology 
transformation. The alliance now includes over 100 of the top 
companies, including IBM, Philips, Dell, Welch Allyn, 
Partners HealthCare, GE, Medtronic, Intel, Boston Scientific, 
Motorola and Samsung. By bringing together all the different 
levels of healthcare technology, from the devices up to the 
healthcare providers, the Alliance is creating a system of 
standards using currently available technologies. The 
Continua Health Alliance recently announced the production 
of its first set of guidelines which will enable most available 
devices to seamlessly function together. Products are now 
being certified and marked with the Continua Health Alliance 
symbol to indicate that a given device is compatible with all 
other Alliance certified products. ST+D have already been 
working with some of the major players in the Continua 
Health Alliance, developing novel technologies for future 
markets, and since late 2007 has been a member of the 
Alliance. 
 
C. Connected HealthCare Systems 
Any single organization or group does not have the 
resources needed to address the complex public health issues 
that need to be resolved to facilitate the introduction and 
implementation of effective and efficient management of 
chronic disease and the ageing. New ‘Connected Health’ 
coalitions will need to be established between the various 
sectors involved to ensure that the advancements in prevention, 
control, and treatment of chronic diseases benefit all. 
Fortunately, the critical mass of interest and political will is 
now coming together in many countries, including in the EU – 
with the goal of connecting the various elements of Healthcare 
provision required for this ‘disruptive’ approach. [A disruptive 
technology or innovation is one that, when introduced, either 
radically transforms markets, creates wholly new markets or 
destroys existing markets for other technologies/strategies.] 
The ‘European Centre for Connected Health’ was recently 
established in Northern Ireland by local Government, with the 
encouragement of the EC, ‘linking up’ of all of the relevant 
‘players’ in HealthCare. “The European Centre for Connected 
Health, based...in Northern Ireland, will focus on developing 
the region as a connected health economy, introducing new 
technologies and working closely with the health and social 
care system to deliver this” [8]. It is anticipated that, once 
successfully implemented in Northern Ireland, which is 
effectively a good-sized, real-world, test-bed for the 
introduction of new systems and technologies, the ‘Connected 
Health’ model will be eventually be adopted throughout 
Europe and possibly elsewhere following adaptation of 
aspects of the model to make it compatible with the varying 
social preferences and the regulatory issues which exist on the 
national or regional level across Europe.  
ST+D has been actively involved in supporting the creation 
of the European Centre for Connected Health in Belfast and 
sees in its creation an ideal opportunity for SMEs to get their 
innovations introduced into clinical settings. Further 
collaborations within Europe and between Europe and the US 
are also key opportunities accruing from this new centre. 
 
D. Taking it to Market 
It is one thing to technically innovate, it is quite another to 
take these innovations successfully onto the complicated and 
conservative medical market. ST+D are taking a multi-
pronged approach to address this challenge. 
 
The Belfast Hospital Trust, including the world-famous 
Royal Victoria Hospital (RVH), has an impressive record in 
medical innovation - including the development by one of the 
ST+D founders of the world’s first portable defibrillation 
service. Work is presently underway in the RVH on the post 
operative monitoring of heart patients using ST+D devices. To 
enable a reduced post-operative stay in the hospital, a 
miniature chest-worn vital signs monitor is being assessed. 
The patient will complete their recovery at home while still 
being monitored remotely by the hospital. There are a number 
of significant issues to be addressed within this trial in order 
to enable the hospital to retain responsibility for patients who 
are no longer physically within the hospital. 
 
ST+D gratefully acknowledge the assistance provided by 
the European Community in the form of several multi-centre 
research projects. These projects have not only provided 
welcome funding, but also the opportunity to collaborate with 
other leading, often large, companies as well as with key 
clinicians and academics. This greatly facilitates the 
development of clinically-viable devices and helps raise the 
profile of an SME such as ST+D, its research and its devices. 
Many of the projects are in niche monitoring areas where the 
route to market may be less challenging. 
The ProeTEX 6th Framework IST Integrated Project 
involves the development of textile-based integrated sensor 
systems for emergency personnel to monitor their wellbeing 
and their environment and to thus improve their safety. 
Additionally, patch-based systems are being developed to 
monitor rescued, possibly injured, civilians at the emergency 
scene in order to facilitate and optimize their survival 
management. It is envisaged that these developments will 
eventually lead to monitoring systems suitable for a wide 
range of other markets including extreme sports, building 
workers and general healthcare [9].  
DIAdvisor is a 7th Framework Programme involving the 
development of a unique tool for diabetics to better predict 
and thereby control their blood glucose levels. The prediction-
based tool will use past and easily available information to 
anticipate how blood glucose levels will develop short term 
and thus optimise the therapy for type I and type II diabetes. 
In addition to blood glucose level and insulin dosing, 
measurements of the patient’s vital signs will be used to assist 
the predictions [10]. 
ST+D regard nonotube array technology as one of the key 
emerging technologies for its sensor development roadmap. 
DEsign, SYnthesis and Growth of Nanotubes for Industrial 
Technology (DESYGN-IT) is 3 year EU-funded STREP 
(Specific Targeted Research Projects) project which 
commenced in 2004. The primary scientific and technical 
objective of this project is to pioneer in Europe the design, 
synthesis, growth and application of nanotubes, nanowires and 
nanotube arrays for industrial technology. ST+D’s 
contribution is particularly in the areas of medical diagnostics, 
sensors and mobile appliances [11].    
 
As an SME, ST+D has long believed in forming strategic 
alliances with major companies who have the where-with-all 
to get the shared technology clinically assessed and into the 
market. This pragmatic approach is not without difficulties, 
however, as often large companies can be relatively slow to 
move and may suddenly put what to them is a minor project 
on the ‘back burner’. Obviously, to a small company, this can 
be problematic.  
ST+D has however successfully cooperated with several 
major companies on projects including Welch Allyn and one 
major US chip company.  
The Center for Innovative Technology for Medicine 
(CIMIT) is a clinically based consortium of Boston-area 
hospitals and engineering schools which includes Harvard 
Medical School, MIT and Partners Healthcare. CIMIT has a 
strong track record in pioneering new medical technologies 
and has recently signed an MoU with ST+D. Under this, co-
operative work is being done to develop a miniaturised 
patient-worn monitor providing information on a patient’s 
heart, respiration, temperature and movement. The devices 
will use the existing hospital wireless networks to give an 
immediate indication of change directly to the clinical teams 
even as patients move around the hospital. This contrasts with 
traditional monitoring which is based around hospital beds. 
 
As stated above, the Centre for European Connected Health 
was recently announced to be set up in Belfast, Northern 
Ireland. The Northern Ireland Health Minister has allocated 
£46m to introduce new approaches to chronic disease 
management with the target of monitoring 5,000 patients 
remotely within 3 years. This world-leading initiative is being 
leveraged by the local development agencies to create a 
remote healthcare technology cluster and ST+D is well 
positioned to be involved. 
 
III. CONCLUSIONS 
Healthcare delivery is set to dramatically change in the near 
future – “a social necessity and an economic opportunity”. 
Although there are many challenges facing the introduction of 
the ‘disruptive’ technologies and systems required, many of 
the underpinning structures are now being put in place. 
 
ACKNOWLEDGMENTS 
ST+D acknowledge with gratitude the support of the EC in 
the following projects- DESYGN-IT, ProeTEX & DIAdvisor. 
The assistance of Dr Chris Nugent in researching the 
background to AAL and its challenges is gratefully 
acknowledged 
REFERENCES 
[1] Ageing and life course,World Health Organization, 
http://www.who.int/ageing/en/. 
[2] United Nations “Population Aging 2002”. 
[3] http://www.continuaalliance.org/ 
[4] Andy Grove, Fortune, April 2003 
[5] Nakita Vodjdani, 1st Global Village Workgroup, February 7th, 2008 
Paris, France. 
[6] Wearable eHealth Systems for Personalised Health Management: State 
of the Art and Future Challenges. Studies in Health Technology and 
Informatics. Editors, Andreas Lymberis and Danilo de Rossi; IOS 
Press. 2004 
[7] Personalised Health Management Systems: The Integration of 
Innovative Sensing, Textile, Information and Communication 
Technologies. Studies in Health Technology and Informatics.  Editors,  
Chris D. Nugent, Paul J. McCullagh, Eric T. McAdams and Andreas 
Lymberis; IOS Press. 2005V 
[8] http://www.eu-cch.org/index.htm 
[9] http://www.proetex.org/ 
[10] http://cordis.europa.eu/fetch?CALLER=PROJ_ICT&ACTION=D&DO
C=77&CAT=PROJ&QUERY=1205498990663&RCN=85459 
[11]  http://www.tcd.ie/Physics/desygnit/index.php 
